Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference

Constance R Chu, Scott Rodeo, Nidhi Bhutani, Laurie R Goodrich, Johnny Huard, James Irrgang, Robert F LaPrade, Christian Lattermann, Ying Lu, Bert Mandelbaum, Jeremy Mao, Louis McIntyre, Allan Mishra, George F Muschler, Nicolas S Piuzzi, Hollis Potter, Kurt Spindler, John M Tokish, Rocky Tuan, Kenneth Zaslav, William Maloney, Constance R Chu, Scott Rodeo, Nidhi Bhutani, Laurie R Goodrich, Johnny Huard, James Irrgang, Robert F LaPrade, Christian Lattermann, Ying Lu, Bert Mandelbaum, Jeremy Mao, Louis McIntyre, Allan Mishra, George F Muschler, Nicolas S Piuzzi, Hollis Potter, Kurt Spindler, John M Tokish, Rocky Tuan, Kenneth Zaslav, William Maloney

Abstract

Concern that misinformation from direct-to-consumer marketing of largely unproven "biologic" treatments such as platelet-rich plasma and cell-based therapies may erode the public trust and the responsible investment needed to bring legitimate biological therapies to patients have resulted in calls to action from professional organizations and governing bodies. In response to substantial patient demand for biologic treatment of orthopaedic conditions, the American Academy of Orthopaedic Surgeons convened a collaborative symposium and established a consensus framework for improving and accelerating the clinical evaluation, use, and optimization of biologic therapies for musculoskeletal diseases. The economic and disease burden of musculoskeletal conditions is high. Of the various conditions discussed, knee osteoarthritis was identified as a "serious condition" associated with substantial and progressive morbidity and emerged as the condition with the most urgent need for clinical trial development. It was also recognized that stem cells have unique characteristics that are not met by minimally manipulated mixed cell preparations. The work group recommended that minimally manipulated cell products be referred to as cell therapy and that the untested and uncharacterized nature of these treatments be clearly communicated within the profession, to patients, and to the public. Minimum standards for product characterization and clinical research should also be followed. A framework for developing clinical trials related to knee OA was agreed upon. In addition to recommendations for development of high-quality multicenter clinical trials, another important recommendation was that physicians and institutions offering biologic therapies commit to establishing high-quality patient registries and biorepository-linked registries that can be used for postmarket surveillance and quality assessments.

References

    1. Evidence-based Medicine: Levels of evidence are described in the table of contents. In this article, references 11, 15, 17, 21, 22, 28, 38, 39 are level I studies. References 23, 24, 25, 26, 34, 35, 36, 41, 44, 47, 51, 52 are level II studies. References 43, 48, 45 are level III studies. References 2, 4, 5, 12, 13, 16, 31, 40, 42, 50 are level IV studies. References 1, 3, 6, 7, 8, 9, 10, 14, 18, 19, 20, 27, 29, 30, 32, 33, 37, 46, 49 are level V expert opinion.

    1. References printed in bold type are those published within the past 5 years.

    1. Chu C, Maloney W, Mao J, Rodeo S, Tuan R, Wang F: AAOS Optimizing Clinical Use of Biologics in Orthopaedic Surgery Planning Team Introductions/Overview of Symposium Goals General Session I: Determining Candidate Biologic Targets for Common Indications. 2018. . Accessed July 17, 2018.
    1. Yelin E, Weinstein S, King T: The burden of musculoskeletal diseases in the United States. Semin Arthritis Rheum 2016;46:259-260.
    1. Jacobs JJ, King TR, Klippel JH, et al. : Beyond the decade: Strategic priorities to reduce the burden of musculoskeletal disease. J Bone Joint Surg Am 2013;95:e1251-e1256.
    1. Piuzzi N, Ng M, Chughtai M, et al. : The stem-cell market for the treatment of knee osteoarthritis: A patient perspective. J Knee Surg 2018;31:551-556.
    1. Turner L, Knoepfler P: Selling stem cells in the USA: Assessing the direct-to-consumer industry. Cell Stem Cell 2016;19:154-157.
    1. Schwarz A: New Procedure Uses Athletes' Own Blood to Treat Injuries. New York Times. 2009, A1 . Accessed July 17, 2018.
    1. Dominici M, Nichols K, Srivastava A, et al. : Positioning a scientific community on unproven cellular therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy 2015;17:1663-1666.
    1. Sipp D, Caulfield T, Kaye J, et al. : Marketing of unproven stem cell–based interventions: A call to action. Sci Transl Med 2017;9:eaag0426.
    1. LaPrade RF, Dragoo JL, Koh JL, Murray IR, Geeslin AG, Chu CR: AAOS research symposium updates and consensus. J Am Acad Orthop Surg 2016;24:e62-e78.
    1. Stem Cell Basics I. . Accessed July 17, 2018.
    1. Luangphakdy V, Boehm C, Pan H, Herrick J, Zaveri P, Muschler GF: Assessment of methods for rapid intraoperative concentration and selection of marrow-derived connective tissue progenitors for bone regeneration using the canine femoral multidefect model. Tissue Eng Part A 2016;22:17-30.
    1. Chahla J, Piuzzi NS, Mitchell JJ, et al. : Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee. J Bone Joint Surg 2016;98:1511-1521.
    1. Piuzzi NS, Chahla J, Jiandong H, et al. : Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: A systematic review of the literature. J Arthroplasty 2017;32:2612-2618.
    1. Muschler GF, Nakamoto C, Griffith LG: Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004;86-A:1541-1558.
    1. Crisan M, Yap S, Casteilla L, et al. : A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-313.
    1. Piuzzi NS, Hussain ZB, Chahla J, et al. : Variability in the preparation, reporting, and use of bone marrow aspirate concentrate in musculoskeletal disorders. J Bone Joint Surg 2018;100:517-525.
    1. Chu CR, Fortier LA, Williams A, et al. : Minimally manipulated bone marrow concentrate compared with microfracture treatment of full-thickness chondral defects. J Bone Joint Surg 2018;100:138-146.
    1. Muschler GF, Midura RJ: Connective tissue progenitors: Practical concepts for clinical applications. Clin Orthop Relat Res 2002;66-80.
    1. Caplan AI: Mesenchymal stem cells. J Orthop Res 1991;9:641-650.
    1. Bianco P, Cao X, Frenette PS, et al. : The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013;19:35-42.
    1. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL: Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 2011;39:266-271.
    1. Mazzocca AD, McCarthy MBR, Chowaniec DM, et al. : Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am 2012;94:308-316.
    1. Xiong G, Lingampalli N, Koltsov JCB, et al. : Men and women differ in the biochemical composition of platelet-rich plasma. Am J Sports Med 2018;46:409-419.
    1. Weibrich G, Kleis WKG, Hafner G, Hitzler WE: Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 2002;30:97-102.
    1. Payne KA, Didiano DM, Chu CR: Donor sex and age influence the chondrogenic potential of human femoral bone marrow stem cells. Osteoarthritis Cartilage 2010;18:705-713.
    1. Maletis GB, Chen J, Inacio MCS, Funahashi TT: Age-related risk factors for revision anterior cruciate ligament reconstruction. Am J Sports Med 2016;44:331-336.
    1. Baer PC, Geiger H: Adipose-derived mesenchymal stromal/stem cells: Tissue localization, characterization, and heterogeneity. Stem Cells Int 2012;2012:812693.
    1. Trivanović D, Jauković A, Popović B, et al. : Mesenchymal stem cells of different origin: Comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression. Life Sci 2015;141:61-73.
    1. Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF: Minimum information for studies evaluating biologics in orthopaedics (MIBO). J Bone Joint Surg 2017;99:809-819.
    1. Etkin CD, Springer BD: The American Joint Replacement Registry: The first 5 years. Arthroplast Today 2017;3:67-69.
    1. Chahla J, Cinque ME, Piuzzi NS, et al. : A call for standardization in platelet-rich plasma preparation protocols and composition reporting. J Bone Joint Surg 2017;99:1769-1779.
    1. Marks P, Gottlieb S: Balancing safety and innovation for cell-based regenerative medicine. N Engl J Med 2018;378:954-959.
    1. FDA, CDER: CBER: Guidance for Industry Expedited Programs for Serious Conditions—Drugs and Biologics. 2014. . Accessed July 17, 2018.
    1. Hawker GA, Croxford R, Bierman AS, et al. : All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: A population based cohort study. PLoS One 2014;9:e91286.
    1. Guccione AA, Felson DT, Anderson JJ, et al. : The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84:351-358.
    1. Ravi B, Croxford R, Austin PC, et al. : The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: Propensity score matched landmark analysis. BMJ 2013;347:f6187.
    1. Osteoarthritis: A serious disease, submitted to the U.S. Food and Drug Administration December 1, 2016. . Accessed July 17, 2018.
    1. Fitzpatrick J, Bulsara M, Zheng MH: The effectiveness of platelet-rich plasma in the treatment of tendinopathy: A meta-analysis of randomized controlled clinical trials. Am J Sports Med 2017;45:226-233.
    1. Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ: Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med 2016;44:792-800.
    1. White DK, Master H: Patient-reported measures of physical function in knee osteoarthritis. Rheum Dis Clin North Am 2016;42:239-252.
    1. Williams AA, Titchenal MR, Andriacchi TP, Chu CR: MRI UTE-T2* profile characteristics correlate to walking mechanics and patient reported outcomes 2 years after ACL reconstruction. Osteoarthritis Cartilage 2018;26:569-579.
    1. Chughtai M, Piuzzi N, Yakubek G, et al. : Use of an app-controlled neuromuscular electrical stimulation system for improved self-management of knee conditions and reduced costs. Surg Technol Int 2017;31:221-226.
    1. Kurtz S, Ong K, Lau E, Mowat F, Halpern M: Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg 2007;89:780-785.
    1. Crema MD, Nogueira-Barbosa MH, Roemer FW, et al. : Three-dimensional turbo spin-echo magnetic resonance imaging (MRI) and semiquantitative assessment of knee osteoarthritis: Comparison with two-dimensional routine MRI. Osteoarthritis Cartilage 2013;21:428-433.
    1. Peterfy CG, Guermazi A, Zaim S, et al. : Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177-190.
    1. Argentieri E, Burge A, Potter H: Magnetic resonance imaging of articular cartilage within the knee. J Knee Surg 2018;31:155-165.
    1. Chu CR, Williams AA, West RV: Quantitative magnetic resonance imaging UTE-T2* mapping of cartilage and meniscus healing after anatomic anterior cruciate ligament reconstruction. Am J Sports Med 2014;42:1847-1856.
    1. Hunter DJ, Guermazi A, Lo GH, et al. : Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI osteoarthritis knee score). Osteoarthritis Cartilage 2011;19:990-1002.
    1. Cyranoski D: Japan relaxes human stem-cell rules. Nature 2009;460:1068.
    1. Mardones R, Jofré CM, Tobar L, Minguell JJ: Mesenchymal stem cell therapy in the treatment of hip osteoarthritis. J Hip Preserv Surg 2017;4:159-163.
    1. Wheaton AJ, Casey FL, Gougoutas AJ, et al. : Correlation of T1rho with fixed charge density in cartilage. J Magn Reson Imaging 2004;20:519-525.
    1. Gallo MC, Wyatt C, Pedoia V, et al. : T1ρ and T2 relaxation times are associated with progression of hip osteoarthritis. Osteoarthritis Cartilage 2016;24:1399-1407.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel